Iclaprim

Andrew Stewardson; M. Lindsay Grayson

Iclaprim

Andrew Stewardson
, M. Lindsay Grayson

Epidemiology and Preventive Medicine Alfred Hospital

Research output: Chapter in Book/Report/Conference proceeding › Chapter (Book) › Other › peer-review

Abstract

Iclaprim (previously known as AR-100 and Ro 48-2622) is a new member of the diaminopyrimidine class of antimicrobials, to which trimethoprim also belongs. As with trimethoprim, iclaprim is an inhibitor of bacterial dihydrofolate reductase (DHFR), an enzyme in the folate synthesis pathway. The two potential advantages of iclaprim compared with trimethoprim are an increased affinity for bacterial DHFR, particularly in Gram-positive bacteria, and activity against trimethoprim-resistant organisms. Iclaprim is therefore a potentially interesting new agent for the treatment of multiresistant Gram-positive infections.

Original language	English
Title of host publication	Kucers the Use of Antibiotics
Subtitle of host publication	A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs
Editors	M. Lindsay Grayson
Place of Publication	Boca Raton FL USA
Publisher	CRC Press
Pages	1775-1783
Number of pages	9
Edition	7th
ISBN (Electronic)	9781498747967
ISBN (Print)	9781498747950
Publication status	Published - 2 Oct 2017

Cite this

@inbook{d208974855d94c1280c1d2096228c4bb,

title = "Iclaprim",

abstract = "Iclaprim (previously known as AR-100 and Ro 48-2622) is a new member of the diaminopyrimidine class of antimicrobials, to which trimethoprim also belongs. As with trimethoprim, iclaprim is an inhibitor of bacterial dihydrofolate reductase (DHFR), an enzyme in the folate synthesis pathway. The two potential advantages of iclaprim compared with trimethoprim are an increased affinity for bacterial DHFR, particularly in Gram-positive bacteria, and activity against trimethoprim-resistant organisms. Iclaprim is therefore a potentially interesting new agent for the treatment of multiresistant Gram-positive infections.",

author = "Andrew Stewardson and \{Lindsay Grayson\}, M.",

year = "2017",

month = oct,

day = "2",

language = "English",

isbn = "9781498747950",

pages = "1775--1783",

editor = "Grayson, \{M. Lindsay \}",

booktitle = "Kucers the Use of Antibiotics",

publisher = "CRC Press",

address = "Australia",

edition = "7th ",

}

TY - CHAP

T1 - Iclaprim

AU - Stewardson, Andrew

AU - Lindsay Grayson, M.

PY - 2017/10/2

Y1 - 2017/10/2

N2 - Iclaprim (previously known as AR-100 and Ro 48-2622) is a new member of the diaminopyrimidine class of antimicrobials, to which trimethoprim also belongs. As with trimethoprim, iclaprim is an inhibitor of bacterial dihydrofolate reductase (DHFR), an enzyme in the folate synthesis pathway. The two potential advantages of iclaprim compared with trimethoprim are an increased affinity for bacterial DHFR, particularly in Gram-positive bacteria, and activity against trimethoprim-resistant organisms. Iclaprim is therefore a potentially interesting new agent for the treatment of multiresistant Gram-positive infections.

AB - Iclaprim (previously known as AR-100 and Ro 48-2622) is a new member of the diaminopyrimidine class of antimicrobials, to which trimethoprim also belongs. As with trimethoprim, iclaprim is an inhibitor of bacterial dihydrofolate reductase (DHFR), an enzyme in the folate synthesis pathway. The two potential advantages of iclaprim compared with trimethoprim are an increased affinity for bacterial DHFR, particularly in Gram-positive bacteria, and activity against trimethoprim-resistant organisms. Iclaprim is therefore a potentially interesting new agent for the treatment of multiresistant Gram-positive infections.

UR - https://www.scopus.com/pages/publications/85056681059

M3 - Chapter (Book)

AN - SCOPUS:85056681059

SN - 9781498747950

SP - 1775

EP - 1783

BT - Kucers the Use of Antibiotics

A2 - Grayson, M. Lindsay

PB - CRC Press

CY - Boca Raton FL USA

ER -

Iclaprim

Abstract

Other files and links

Research output

Iclaprim

Cite this